Analysts Viewpoint
Investing in Outlook Therapeutics Inc (OTLK): What You Must Know
Outlook Therapeutics Inc’s filing revealed that its Chief Financial Officer KENYON LAWRENCE A acquired Company’s shares for reported $28446.0 on
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.